Johnson & Johnson (JNJ) Return on Equity (ROE): 25.92%
Is Johnson & Johnson’s return on equity (ROE) high or low?
Johnson & Johnson's return on equity (ROE) of 25.92% is 13% below its 5-year average of 29.75%, near the low end of its 5-year range (19.68%–51.11%).
As of Thursday, June 11, 2026. 1.35% below its 12-month average of 26.27%.
JNJ Return on Equity (ROE) Chart
JNJ Average Return on Equity (ROE) Chart
JNJ Current vs Average Return on Equity (ROE) Chart
JNJ Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
25.92%
RETURN ON EQUITY (ROE) AVG TTM
26.27%
RETURN ON EQUITY (ROE) AVG 3Y
31.76%
RETURN ON EQUITY (ROE) AVG 5Y
29.75%
RETURN ON EQUITY (ROE) AVG 10Y
25.16%
RETURN ON EQUITY (ROE) AVG 15Y
23.51%
RETURN ON EQUITY (ROE) AVG 20Y
24.25%
CURRENT VS TTM AVG
-1.35%
CURRENT VS 3Y AVG
-18.38%
CURRENT VS 5Y AVG
-12.86%
CURRENT VS 10Y AVG
+3.01%
CURRENT VS 15Y AVG
+10.26%
CURRENT VS 20Y AVG
+6.87%
JNJ Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $577.73B | 25.92% | 26.27% | 31.76% | 29.75% |
| Pfizer Inc. (PFE) | $149.61B | 8.31% | 9.04% | 13.32% | 16.07% |
| Merck & Co., Inc. (MRK) | $298.23B | 19.48% | 35.83% | 26.05% | 27.71% |
| AbbVie Inc. (ABBV) | $399.86B | 13.23% | -0.29% | 28.74% | 37.53% |
| Eli Lilly and Company (LLY) | $1.10T | 81.01% | 76.20% | 64.92% | 71.94% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 36.25% | -8.30% | 7.76% | 4.45% |
Return Analysis
ROE
25.9%
ROA
10.5%
Johnson & Johnson Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Johnson & Johnson (JNJ)?
- The return on equity (ROE) for JNJ stock is 25.92%.
- Is Johnson & Johnson's return on equity (ROE) high or low?
- Johnson & Johnson's return on equity (ROE) of 25.92% is 13% below its 5-year average of 29.75%, near the low end of its 5-year range (19.68%–51.11%).
- What is the TTM average return on equity (ROE) for Johnson & Johnson (JNJ)?
- The TTM average return on equity (ROE) for JNJ stock is 26.27%.
- What is the 3Y average return on equity (ROE) for Johnson & Johnson (JNJ)?
- The 3Y average return on equity (ROE) for JNJ stock is 31.76%.
- What is the 5Y average return on equity (ROE) for Johnson & Johnson (JNJ)?
- The 5Y average return on equity (ROE) for JNJ stock is 29.75%.
- What is the 10Y average return on equity (ROE) for Johnson & Johnson (JNJ)?
- The 10Y average return on equity (ROE) for JNJ stock is 25.16%.
- What is the 15Y average return on equity (ROE) for Johnson & Johnson (JNJ)?
- The 15Y average return on equity (ROE) for JNJ stock is 23.51%.
- What is the 20Y average return on equity (ROE) for Johnson & Johnson (JNJ)?
- The 20Y average return on equity (ROE) for JNJ stock is 24.25%.
Johnson & Johnson Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-28 | 32.87% |
| 2024-12-29 | 19.68% |
| 2023-12-31 | 51.11% |
| 2023-01-01 | 23.36% |
| 2022-01-02 | 28.20% |
| 2021-01-03 | 23.25% |
| 2019-12-31 | 25.42% |
| 2018-12-31 | 25.60% |
| 2017-12-31 | 2.16% |
| 2016-12-31 | 23.49% |
| 2015-12-31 | 21.66% |
| 2014-12-31 | 23.40% |
| 2013-12-31 | 18.68% |
| 2012-12-31 | 16.74% |
| 2011-12-31 | 16.94% |
| 2010-12-31 | 23.57% |
| 2009-12-31 | 24.25% |
| 2008-12-31 | 30.46% |
| 2007-12-31 | 24.41% |
| 2006-12-31 | 28.11% |
| 2005-12-31 | 25.99% |
| 2004-12-31 | 25.71% |
| 2003-12-31 | 26.79% |
| 2002-12-31 | 29.07% |
| 2001-12-31 | 23.39% |
| 2000-12-31 | 24.29% |
| 1999-12-31 | 26.36% |
| 1998-12-31 | 21.33% |
| 1997-12-31 | 26.73% |
| 1996-12-31 | 26.64% |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato